Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Phase 3 INDIGO open-label extension findings showed sustained clinical activity. Additional secondary-endpoint analyses found significantly fewer patients experienced clinically meaningful cumulative glucocorticoid toxicity at week 52.
The company announced a presentation of new obexelimab data in IgG4-related disease at the 6th International Symposium on IgG4-Related Disease.
Zenas BioPharma will present updates on orelabrutinib and obexelimab at MSToronto2026, including Phase 3 trial designs for orelabrutinib in non-active secondary progressive multiple sclerosis and primary progressive multiple sclerosis. New results from a Phase 2 relapsing-remitting multiple sclerosis study of orelabrut
For best results when printing this announcement, please click on link below: RNS Number: 0622W BioPharma Credit PLC 24 September 2026 24 September 2026 BIOPHARMA CREDIT PLC ("BPCR" or "the Company") HALF YEAR REPORT FOR THE YEAR ENDED 30 JUNE 2026 BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt inv